Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

BACKGROUND: In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab‐paclitaxel (GnP) have been publicly funded for first‐line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015. We examined the real‐world effectiveness and safety of FFX vs GnP f...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Chan, Kelvin K. W., Guo, Helen, Cheng, Sierra, Beca, Jaclyn M., Redmond‐Misner, Ruby, Isaranuwatchai, Wanrudee, Qiao, Lucy, Earle, Craig, Berry, Scott R., Biagi, James J., Welch, Stephen, Meyers, Brandon M., Mittmann, Nicole, Coburn, Natalie, Arias, Jessica, Schwartz, Deborah, Dai, Wei F., Gavura, Scott, McLeod, Robin, Kennedy, Erin D.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6943167/
https://ncbi.nlm.nih.gov/pubmed/31724340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2705
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares